Treatment of Sual-e-Yabis (Dry Cough) with Unani medicine Habb-e-Luab-e-Behidana

An open-label, Multicentric Clinical Validation Study to Evaluate the Efficacy and Safety of Unani Pharmacopoeial formulation â?? Habb-e-Luab-e-Behidana in Sual-e-Yabis (Dry Cough)

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2021/12/038808

Enrollment

220

Registered

2021-12-21

Start date

Unknown

Completion date

Unknown

Last updated

2022-02-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: R05- Cough

Interventions

Intervention1: Habb-e-Luab-e-Behidana: 1 pill (250 mg) twice daily to be taken with warm water for two weeks Control Intervention1: NIL: NIL

Eligibility

Inclusion criteria

Inclusion criteria: 1. Patients of either sex in the age group of 18-60 years. 2. Sual-e-Yabis (Dry Cough) of < 3 weeks duration

Exclusion criteria

Exclusion criteria: 1. Acute Upper Respiratory Tract Infections (URI or URTI) 2. Acute Lower Respiratory Tract Infections (LRI or LRTI) including pneumonia, lung abscess, and acute bronchitis. 3. Chronic obstructive airway disease (COAD) including chronic bronchitis and emphysema. 4. Bronchiectasis, pulmonary tuberculosis, pulmonary oedema, interstitial pulmonary fibrosis 5. Tumours of larynx, bronchi, and lungs 6. Drug-induced Cough (e.g., ACE Inhibitors) 7. Diabetes Mellitus, Hypertension 8. Known cases of severe hepatic, renal or cardiac ailments 9. H/o addiction (smoking, alcohol, drugs) 10. Pregnant and lactating women

Design outcomes

Primary

Measure	Time frame
Improvement in sign and symptoms of Sual-e-Yabis (Dry Cough)Timepoint: 2 weeks	—

Secondary

Measure	Time frame
Haematological and biochemical assessment for safety assessmentTimepoint: Investigations will be done at baseline and end of treatment	—

Countries

India

Contacts

Public ContactDr Pradeep Kumar

Central Council for Research in Unani Medicine (CCRUM)

ccrum507@rediffmail.com9213511298

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026